The burden of patent ductus arteriosus (PDA) continues to be significant. In view of marked
differences in preterm infants versus more mature, term counterparts (viewed on a …

In many preterm infants, the ductus arteriosus remains patent beyond the first few days of
life. This prolonged patency is associated with numerous adverse outcomes, but the extent …

Background Cyclooxygenase inhibitors are commonly used in infants with patent ductus
arteriosus (PDA), but the benefit of these drugs is uncertain. Methods In this multicenter …

Targeted neonatal echocardiography (TNE) involves the use of comprehensive
echocardiography to appraise cardiovascular physiology and neonatal hemodynamics to …

OBJECTIVES Percutaneous patent ductus arteriosus (PDA) closure is becoming the
standard of care for definitive closure in progressively smaller and younger neonates. The …

Rationale: Increasing survival of extremely preterm infants with a stable rate of severe
intraventricular hemorrhage represents a growing health risk for neonates. Objectives: To …

Objective There is no consensus on the definition of a hemodynamically significant patent
ductus arteriosus (hsPDA). In this review article, our objective is to discuss the main …

Importance Persistent patent ductus arteriosus (PDA) in preterm infants is associated with
increased mortality and respiratory morbidities, including bronchopulmonary dysplasia …

Echocardiography in the neonatal intensive care unit has led to improvements in our ability
to assess the neonatal heart in health and disease. Advances in neonatal cardiac imaging …

The persistence of a patent ductus arteriosus (PDA) is a common condition in preterm
infants with a prevalence inversely proportional to gestational age. PDA is associated with …